Results 51 to 60 of about 12,338 (205)
Oncostatin M suppresses browning of white adipocytes via gp130-STAT3 signaling
Molecular Metabolism, 2021 Objective: Obesity is associated with low-grade adipose tissue inflammation and locally elevated levels of several glycoprotein 130 (gp130) cytokines.
Pim P. van Krieken +5 more
doaj +1 more source
Cloning and characterization of human oncostatin M promoter [PDF]
Nucleic Acids Research, 1999 Oncostatin M (OSM), an IL-6 subfamily cytokine, inhibits proliferation and causes morphological changes in many tumor cell lines. GM-CSF, phorbol-12-myristate-13-acetate (PMA), and lipopolysaccharide (LPS) induce OSM expression. To investigate the mechanisms governing OSM promoter activity, we have cloned and partially sequenced an 8.5 kb fragment of ...
Y, Ma +4 more
openaire +2 more sources
Animal Models and Experimental Medicine, EarlyView.Substantial advances have been achieved in the development of humanized mouse models, which have proven highly valuable in evaluating cancer immunotherapies and elucidating the mechanisms of infectious diseases. There is now a growing shift in research toward larger animal models—such as pigs—that offer greater physiological similarity to humans ...
Yanan Lyu, Yong‐Guang Yang, Zheng Hu
wiley +1 more source
Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis
Arthritis &Rheumatology, EarlyView.Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm +2 more
wiley +1 more source
Expression of nephronectin is inhibited by oncostatin M via both JAK/STAT and MAPK pathways
FEBS Open Bio, 2015 Nephronectin (Npnt), also called POEM, is an extracellular matrix protein considered to play critical roles as an adhesion molecule in the development and functions of various tissues, such as the kidneys, liver, and bones.
Tamaki Kurosawa +12 more
doaj +1 more source
Oncostatin M Induces Angiogenesis In Vitro and In Vivo [PDF]
Arteriosclerosis, Thrombosis, and Vascular Biology, 1999 Abstract—Neovascularization of the atherosclerotic plaque is responsible for its weakening and consequently for the complications of vascular disease. Macrophages are a source of growth factors that can modulate angiogenesis. In this study, we analyzed the effect of oncostatin M (OSM) on angiogenesis, as it could be involved in the development of ...
M, Vasse +7 more
openaire +2 more sources
Arthritis &Rheumatology, EarlyView.Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó +84 more
wiley +1 more source
Oncostatin M [OSM] protein immuno-expression in oral squamous cell carcinoma – A prospective study
Oral Oncology ReportsBackground: An important factor in the progression of tumours is the formation of blood vessels in the tumour stroma. When there is an upregulation of angiogenesis stimulators or a downregulation of angiogenesis inhibitors, the tumour may manifest its ...
Sunil Prakash +3 more
doaj +1 more source
A role for oncostatin M in inflammatory bowel disease [PDF]
Nature Medicine, 2017 A new study identifies oncostatin M (OSM) as a potential biomarker and therapeutic target for anti-tumor necrosis factor (TNF)-refractory inflammatory bowel disease (IBD), and pinpoints mucosal stromal cells as key players in OSM-mediated inflammation.
Walter M, Kim +2 more
openaire +2 more sources
JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series
JEADV Clinical Practice, EarlyView.ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni +6 more
wiley +1 more source